Table 1 summarizes all additional mutations described in patients with PV, ET, and PMF with their respective types and frequencies. The aim of this short review is to highlight the impact of NGS on the diagnostic, prognostic, and therapeutic management of patients with PV, ET, and PMF in 2022. The SF3B1 mutation (associated with myelodysplastic syndrome) is not within the scope of this review. This evidence concerns the gene SF3B1 and acquired polycythemia vera.